Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Tract-specific and age-related variations of the spinal cord microstructure: a multi-parametric MRI study using diffusion tensor imaging (DTI) and inhomogeneous magnetization transfer (ihMT).
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Association Between Sleep Problems and Perceived Cognitive Dysfunction Over 12 Months in Individuals with Multiple Sclerosis.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Convergence through Complexity: How to Cure Brain Disease; Orion Bionetworks 2nd Annual Conference
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Novantrone
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression.
Atypical facial pain in multiple sclerosis caused by spinal cord seizures: a case report and review of the literature.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Multiple sclerosis: association with HL-A3.
Assessment of cancer risk with β-interferon treatment for multiple sclerosis.
Episode 5 with Dr. Anne Cross on the year in MS research
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Zebrafish as a model to investigate CNS myelination.
Burden of neurological conditions in Canada.
Dimethyl fumarate induces necroptosis in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients

Pages